Alembic Pharmaceuticals, 533573, APLLTD Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

17,724.10
30.38
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

18,829.57
1.22%
3.41

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

11.72
6.22
5.49

EBITDA CAGR (%)

10 Years
5 Years
3 Years

8.97
-5.14
1.30

PAT CAGR (%)

10 Years
5 Years
3 Years

8.10
-5.77
5.74

P:E (Median)

8 Years
5 Years
3 Years

24.72
27.70
32.78

P:BV (Average)

8 Years
5 Years
3 Years

3.78
3.48
3.28

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.76
16.62
18.77

Earnings Forecasts:

Description 2024 2025 2026 2027
Adj EPS 31.33 32.75 42.45 53.64
P/E Ratio 34.73 33.23 25.63 20.29
Revenue 6229 6708 7507 8350
EBITDA 933 1085 1340 1626
Net Income 616 645 835 1054
ROA 9.8 10.7 12.8 14.3
P/B Ratio 4.44 4.07 3.64 3.21
ROE 13.4 12.86 15.07 17.19
FCFF 429.98 475.63 646.25 750.43
FCFF Yield 1.96 2.16 2.94 3.41

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 1,570.64 1,474.55 6.52% 1,406.09 1,588.39 -11.48% 1,580.35 1,478.84 6.86% 1,475.56 1,332.27 10.76%
Expenses 1,399.98 1,186.36 18.01% 1,226.26 1,251.25 -2.00% 1,320.86 1,271.38 3.89% 1,184.13 1,166.55 1.51%
EBITDA 170.66 288.19 -40.78% 179.83 337.14 -46.66% 259.49 207.46 25.08% 291.43 165.72 75.86%
EBIDTM 10.87% 19.54% 12.79% 21.23% 16.42% 14.03% 19.75% 12.44%
Other Income 13.21 7.22 82.96% 15.46 3.30 368.48% 16.06 8.95 79.44% 3.14 11.85 -73.50%
Interest 23.71 10.13 134.06% 21.79 14.66 48.64% 18.28 15.39 18.78% 12.69 14.29 -11.20%
Depreciation 68.60 69.12 -0.75% 69.69 69.08 0.88% 70.12 67.18 4.38% 68.68 65.75 4.46%
PBT 91.56 216.16 -57.64% 103.81 256.70 -59.56% 200.02 133.84 49.45% 213.20 97.53 118.60%
Tax 16.22 14.29 13.51% 18.00 23.46 -23.27% 34.24 0.00 0 37.01 0.00 0
PAT 75.34 201.87 -62.68% 85.81 233.24 -63.21% 165.78 133.84 23.86% 176.19 97.53 80.65%
PATM 4.80% 13.69% 6.10% 14.68% 10.49% 9.05% 11.94% 7.32%
EPS 3.83 10.27 -62.71% 4.36 11.86 -63.24% 8.43 6.81 23.79% 8.96 4.96 80.65%

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 1,769.64 1,516.97 16.66% 1,692.75 1,630.57 3.81% 1,647.98 1,594.93 3.33% 1,561.73 1,486.15 5.09%
Expenses 1,497.71 1,256.92 19.16% 1,432.52 1,364.21 5.01% 1,408.71 1,386.69 1.59% 1,324.90 1,287.45 2.91%
EBITDA 271.93 260.05 4.57% 260.23 266.36 -2.30% 239.27 208.24 14.90% 236.83 198.70 19.19%
EBIDTM 15.37% 17.14% 15.37% 16.34% 14.52% 13.06% 15.16% 13.37%
Other Income 14.19 3.60 294.17% 9.50 2.89 228.72% 16.74 10.15 64.93% 2.10 11.66 -81.99%
Interest 24.52 10.94 124.13% 22.26 15.17 46.74% 18.81 15.69 19.89% 13.18 14.39 -8.41%
Depreciation 68.99 69.48 -0.71% 70.04 69.45 0.85% 70.51 67.56 4.37% 69.04 66.18 4.32%
PBT 192.61 183.23 5.12% 177.43 184.63 -3.90% 179.56 135.14 32.87% 156.71 129.79 20.74%
Tax 35.32 4.63 662.85% 40.09 4.13 870.70% 27.28 -1.93 - 22.49 9.16 145.52%
PAT 157.29 178.60 -11.93% 137.34 180.50 -23.91% 152.28 137.07 11.10% 134.22 120.63 11.27%
PATM 8.89% 11.77% 8.11% 11.07% 9.24% 8.59% 8.59% 8.12%
EPS 7.98 9.07 -12.02% 7.04 9.18 -23.31% 7.81 6.95 12.37% 6.85 6.14 11.56%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 6,032.64 5,874.06 5,149.00 5,035.40 5,066.88 4,132.56 3,660.28 2,945.26 2,985.90 3,009.02 2,019.00 Net Sales Growth 2.70% 14.08% 2.26% -0.62% 22.61% 12.90% 24.28% -1.36% -0.77% 49.04% Cost Of Goods Sold 1,788.77 1,800.35 1,660.13 1,502.21 1,304.03 1,045.87 1,000.08 893.36 915.74 854.53 639.54 Gross Profit 4,243.87 4,073.71 3,488.87 3,533.19 3,762.85 3,086.69 2,660.20 2,051.90 2,070.16 2,154.49 1,379.46 GP Margin 70.35% 69.35% 67.76% 70.17% 74.26% 74.69% 72.68% 69.67% 69.33% 71.60% 68.32% Total Expenditure 5,131.23 4,876.27 4,484.97 4,126.63 3,617.71 2,940.87 2,800.98 2,346.65 2,353.36 2,061.47 1,614.19 Power & Fuel Cost - 173.32 151.19 120.50 118.31 97.43 88.44 70.21 64.13 58.84 43.29 % Of Sales - 2.95% 2.94% 2.39% 2.33% 2.36% 2.42% 2.38% 2.15% 1.96% 2.14% Employee Cost - 1,335.91 1,094.82 1,062.30 976.13 806.37 684.45 582.72 527.46 453.32 296.57 % Of Sales - 22.74% 21.26% 21.10% 19.26% 19.51% 18.70% 19.79% 17.67% 15.07% 14.69% Manufacturing Exp. - 348.85 386.28 374.69 369.82 323.09 254.55 226.57 241.01 184.80 250.73 % Of Sales - 5.94% 7.50% 7.44% 7.30% 7.82% 6.95% 7.69% 8.07% 6.14% 12.42% General & Admin Exp. - 497.23 464.08 390.16 377.29 311.21 319.33 269.55 283.40 219.09 137.57 % Of Sales - 8.46% 9.01% 7.75% 7.45% 7.53% 8.72% 9.15% 9.49% 7.28% 6.81% Selling & Distn. Exp. - 673.69 679.85 647.93 445.87 318.14 422.79 273.56 298.84 266.86 230.20 % Of Sales - 11.47% 13.20% 12.87% 8.80% 7.70% 11.55% 9.29% 10.01% 8.87% 11.40% Miscellaneous Exp. - 46.92 48.62 28.84 26.26 38.76 31.34 30.68 22.78 24.03 230.20 % Of Sales - 0.80% 0.94% 0.57% 0.52% 0.94% 0.86% 1.04% 0.76% 0.80% 0.81% EBITDA 901.41 997.79 664.03 908.77 1,449.17 1,191.69 859.30 598.61 632.54 947.55 404.81 EBITDA Margin 14.94% 16.99% 12.90% 18.05% 28.60% 28.84% 23.48% 20.32% 21.18% 31.49% 20.05% Other Income 47.87 32.05 3.85 51.17 84.08 145.96 25.79 40.59 3.28 42.00 5.61 Interest 76.47 54.47 49.00 17.02 12.98 25.19 14.87 2.22 3.21 3.68 3.14 Depreciation 277.09 271.14 272.95 284.92 182.53 135.67 105.59 101.76 82.90 71.86 44.41 PBT 608.59 704.23 345.93 658.00 1,337.74 1,176.79 764.63 535.22 549.71 914.01 362.86 Tax 105.47 37.75 -0.80 114.45 241.20 197.39 153.42 113.23 119.08 215.27 76.25 Tax Rate 17.33% 5.36% -0.23% 17.39% 18.03% 16.92% 20.06% 21.16% 21.66% 23.55% 21.01% PAT 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 286.61 PAT before Minority Interest 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 286.61 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 8.34% 11.35% 6.73% 10.79% 21.64% 23.46% 16.70% 14.33% 14.42% 23.22% 14.20% PAT Growth -24.51% 92.22% -36.21% -50.43% 13.12% 58.60% 44.84% -2.01% -38.37% 143.79% EPS 25.59 33.90 17.64 27.65 55.78 49.31 31.09 21.46 21.90 35.54 14.58

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 6,672.10 6,228.62 5,652.62 5,305.78 5,393.14 4,605.76 3,934.69 3,130.81 3,134.61 3,165.99 2,056.13 Net Sales Growth 7.12% 10.19% 6.54% -1.62% 17.10% 17.06% 25.68% -0.12% -0.99% 53.98% Cost Of Goods Sold 1,793.36 1,715.08 1,708.82 1,446.43 1,257.35 1,039.38 992.71 886.19 887.57 823.95 639.85 Gross Profit 4,878.74 4,513.54 3,943.80 3,859.35 4,135.79 3,566.38 2,941.98 2,244.62 2,247.04 2,342.04 1,416.28 GP Margin 73.12% 72.46% 69.77% 72.74% 76.69% 77.43% 74.77% 71.69% 71.68% 73.97% 68.88% Total Expenditure 5,663.84 5,296.00 4,944.56 4,431.64 3,913.05 3,391.69 3,078.87 2,515.55 2,519.90 2,160.88 1,660.92 Power & Fuel Cost - 173.37 151.54 120.84 118.72 102.40 88.86 70.35 64.20 58.89 43.31 % Of Sales - 2.78% 2.68% 2.28% 2.20% 2.22% 2.26% 2.25% 2.05% 1.86% 2.11% Employee Cost - 1,446.29 1,169.13 1,133.00 1,051.17 906.44 746.69 622.81 558.83 472.85 306.76 % Of Sales - 23.22% 20.68% 21.35% 19.49% 19.68% 18.98% 19.89% 17.83% 14.94% 14.92% Manufacturing Exp. - 387.71 409.37 379.15 372.18 368.41 269.25 244.53 289.79 271.51 263.38 % Of Sales - 6.22% 7.24% 7.15% 6.90% 8.00% 6.84% 7.81% 9.24% 8.58% 12.81% General & Admin Exp. - 525.84 492.64 413.90 391.24 339.82 340.56 283.43 299.79 233.28 145.68 % Of Sales - 8.44% 8.72% 7.80% 7.25% 7.38% 8.66% 9.05% 9.56% 7.37% 7.09% Selling & Distn. Exp. - 996.88 952.30 890.38 687.41 531.19 590.28 380.21 393.14 274.14 244.69 % Of Sales - 16.00% 16.85% 16.78% 12.75% 11.53% 15.00% 12.14% 12.54% 8.66% 11.90% Miscellaneous Exp. - 50.83 60.76 47.94 34.98 104.05 50.52 28.03 26.58 26.26 244.69 % Of Sales - 0.82% 1.07% 0.90% 0.65% 2.26% 1.28% 0.90% 0.85% 0.83% 0.84% EBITDA 1,008.26 932.62 708.06 874.14 1,480.09 1,214.07 855.82 615.26 614.71 1,005.11 395.21 EBITDA Margin 15.11% 14.97% 12.53% 16.48% 27.44% 26.36% 21.75% 19.65% 19.61% 31.75% 19.22% Other Income 42.53 29.04 3.04 50.49 87.48 13.88 27.14 34.87 2.58 8.83 12.09 Interest 78.77 56.19 50.17 17.73 16.02 27.16 18.41 3.40 5.23 5.43 3.81 Depreciation 278.58 272.67 275.43 286.78 183.47 157.32 115.23 105.46 82.97 72.21 44.41 PBT 706.31 632.80 385.50 620.12 1,368.08 1,043.47 749.32 541.27 529.09 936.30 359.07 Tax 125.18 16.01 12.60 104.46 253.32 199.18 156.75 120.36 122.19 216.12 76.35 Tax Rate 17.72% 2.53% 3.27% 16.85% 18.52% 19.92% 20.92% 22.24% 23.09% 23.08% 21.26% PAT 581.13 615.82 341.99 520.94 1,114.76 828.76 593.65 420.72 406.99 720.18 282.72 PAT before Minority Interest 582.55 615.82 341.99 520.94 1,114.76 800.64 592.57 420.91 406.90 720.18 282.72 Minority Interest 1.42 0.00 0.00 0.00 0.00 28.12 1.08 -0.19 0.09 0.00 0.00 PAT Margin 8.71% 9.89% 6.05% 9.82% 20.67% 17.99% 15.09% 13.44% 12.98% 22.75% 13.75% PAT Growth -5.78% 80.07% -34.35% -53.27% 34.51% 39.60% 41.10% 3.37% -43.49% 154.73% EPS 29.56 31.32 17.40 26.50 56.70 42.15 30.20 21.40 20.70 36.63 14.38

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 4,908.91 4,414.29 5,290.34 5,101.81 3,346.02 2,712.41 2,194.63 1,867.32 1,530.73 833.57 Share Capital 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 37.70 Total Reserves 4,869.60 4,374.98 5,251.03 5,062.50 3,308.32 2,674.71 2,156.93 1,829.62 1,493.03 795.86 Non-Current Liabilities 83.59 86.67 204.25 403.08 1,079.25 595.88 585.07 101.00 83.91 72.44 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.80 Unsecured Loans 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 0.00 Long Term Provisions 109.51 106.20 95.82 85.52 73.21 51.32 40.43 57.22 28.23 9.36 Current Liabilities 1,368.40 1,551.30 1,694.45 1,378.36 1,453.49 1,397.76 1,011.69 658.79 763.15 605.15 Trade Payables 619.96 595.86 570.21 527.00 393.17 472.75 601.98 430.11 499.76 316.45 Other Current Liabilities 222.34 250.41 515.60 557.86 222.12 375.65 140.28 80.35 51.32 44.29 Short Term Borrowings 420.04 635.07 430.00 0.02 800.04 359.98 121.53 8.28 0.00 149.81 Short Term Provisions 106.06 69.96 178.64 293.48 38.16 189.38 147.90 140.05 212.07 94.60 Total Liabilities 6,360.90 6,052.26 7,189.04 6,883.25 5,878.76 4,706.05 3,791.39 2,627.11 2,377.79 1,511.16 Net Block 2,535.66 2,377.47 1,771.10 1,773.82 1,276.46 1,085.44 918.30 799.01 697.25 488.68 Gross Block 3,859.16 3,441.30 2,733.11 2,452.31 1,761.68 1,435.06 1,162.61 948.64 1,082.45 802.85 Accumulated Depreciation 1,323.50 1,063.83 962.01 678.49 485.22 349.62 244.31 149.63 385.20 314.17 Non Current Assets 3,331.16 3,272.05 4,329.58 4,148.87 3,727.40 2,713.03 2,002.20 1,286.33 857.01 670.18 Capital Work in Progress 524.36 601.28 2,304.24 2,182.53 1,569.98 1,106.89 740.64 347.75 92.34 83.14 Non Current Investment 226.68 229.27 219.36 156.12 833.25 506.39 298.89 103.04 37.46 33.33 Long Term Loans & Adv. 44.46 64.03 34.88 36.40 47.71 14.31 44.37 36.53 29.96 65.03 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 3,029.74 2,780.21 2,859.46 2,734.38 2,151.36 1,993.02 1,789.19 1,340.78 1,520.78 840.98 Current Investments 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 1,353.07 1,275.13 1,396.83 1,341.95 1,073.18 891.42 669.93 574.62 533.72 382.48 Sundry Debtors 1,340.12 1,201.20 988.33 421.86 784.11 539.78 621.66 467.41 371.50 337.94 Cash & Bank 26.49 28.46 21.90 61.44 37.13 150.80 15.63 7.21 284.81 4.41 Other Current Assets 310.06 48.19 44.71 71.55 256.94 411.02 481.97 291.54 330.75 116.15 Short Term Loans & Adv. 256.80 227.23 407.69 650.61 234.58 397.95 458.60 285.95 324.85 116.15 Net Current Assets 1,661.34 1,228.91 1,165.01 1,356.02 697.87 595.26 777.50 681.99 757.63 235.83 Total Assets 6,360.90 6,052.26 7,189.04 6,883.25 5,878.76 4,706.05 3,791.39 2,627.11 2,377.79 1,511.16

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 4,818.20 4,370.47 5,237.54 5,066.98 3,219.42 2,718.83 2,220.14 1,902.33 1,597.36 884.64 Share Capital 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 37.70 Total Reserves 4,778.89 4,331.16 5,198.23 5,027.67 3,181.72 2,681.13 2,182.44 1,864.63 1,559.66 846.94 Non-Current Liabilities 2.75 52.42 162.07 361.16 1,046.98 570.06 576.20 94.15 84.02 72.44 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.80 Unsecured Loans 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 0.00 Long Term Provisions 109.51 106.20 95.82 85.52 74.51 52.03 40.76 57.22 28.23 9.36 Current Liabilities 1,520.28 1,640.80 1,830.59 1,533.26 1,751.61 1,663.65 1,267.18 813.96 944.19 684.09 Trade Payables 735.64 679.81 706.39 668.78 625.93 644.34 759.32 500.73 565.65 324.94 Other Current Liabilities 223.66 251.19 516.51 557.92 226.98 380.19 142.89 81.28 51.80 44.56 Short Term Borrowings 430.45 635.87 430.00 0.02 860.50 429.13 207.78 88.51 113.71 219.70 Short Term Provisions 130.53 73.93 177.69 306.54 38.20 209.99 157.19 143.44 213.03 94.88 Total Liabilities 6,341.23 6,063.69 7,230.20 6,961.40 5,989.05 4,951.75 4,063.83 2,810.55 2,625.57 1,641.17 Net Block 2,546.71 2,398.45 1,797.85 1,788.42 1,551.84 1,158.45 993.38 799.40 708.09 546.87 Gross Block 3,875.21 3,467.50 2,840.33 2,545.39 2,132.41 1,522.57 1,242.47 950.09 1,093.63 861.06 Accumulated Depreciation 1,328.50 1,069.05 1,042.48 756.97 580.57 364.12 249.09 150.69 385.54 314.19 Non Current Assets 3,197.39 3,149.80 4,255.37 4,056.96 3,526.30 2,820.02 2,116.31 1,316.80 917.30 750.43 Capital Work in Progress 524.36 601.28 2,304.24 2,182.53 1,846.18 1,551.23 1,010.15 396.28 92.52 83.14 Non Current Investment 93.02 96.33 118.40 49.31 17.62 48.76 41.64 49.88 53.43 2.26 Long Term Loans & Adv. 33.30 53.74 34.88 36.70 110.66 61.58 71.14 71.24 29.96 118.15 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.30 0.00 Current Assets 3,143.84 2,913.89 2,974.83 2,904.44 2,462.75 2,131.73 1,947.52 1,493.75 1,708.27 890.74 Current Investments 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 1,643.54 1,475.27 1,609.70 1,486.15 1,187.54 967.27 733.93 632.75 569.79 382.77 Sundry Debtors 1,024.84 1,046.41 807.13 348.60 864.75 488.92 526.34 338.82 350.48 361.17 Cash & Bank 126.57 82.27 69.43 105.84 80.75 205.62 89.92 159.60 450.83 26.83 Other Current Assets 348.89 55.32 51.65 78.67 329.71 469.92 597.33 362.58 337.17 119.98 Short Term Loans & Adv. 289.03 254.62 436.92 698.21 301.61 451.71 569.84 355.02 330.08 119.98 Net Current Assets 1,623.56 1,273.09 1,144.24 1,371.18 711.14 468.08 680.34 679.79 764.08 206.65 Total Assets 6,341.23 6,063.69 7,230.20 6,961.40 5,989.05 4,951.75 4,063.83 2,810.55 2,625.57 1,641.17

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 772.77 730.25 545.26 1,388.48 539.75 808.80 304.55 327.16 847.52 180.08 PBT 704.23 345.93 658.01 1,337.74 1,166.79 764.63 535.22 549.71 914.01 362.86 Adjustment 284.21 448.49 413.35 92.60 30.14 91.48 81.90 84.88 72.96 34.84 Changes in Working Capital -205.64 -10.39 -397.30 198.56 -460.39 110.38 -188.46 -189.44 56.63 -148.53 Cash after chg. in Working capital 782.80 784.03 674.06 1,628.90 736.54 966.49 428.66 445.15 1,043.60 249.18 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -10.03 -53.78 -128.80 -240.42 -196.79 -157.69 -124.11 -117.99 -196.08 -69.10 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -329.02 -460.98 -368.72 -835.72 -822.32 -753.60 -793.58 -510.97 -291.91 -198.51 Net Fixed Assets -340.94 994.77 -402.51 -1,303.18 -789.71 -638.70 -606.86 -121.60 -288.80 -200.26 Net Investments 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 0.00 Others 9.33 -1,445.84 -89.94 -22.70 294.25 92.60 9.13 -323.79 1.02 1.75 Cash from Financing Activity -445.29 -261.16 -216.64 -533.75 166.13 79.67 497.80 -96.06 -276.05 17.50 Net Cash Inflow / Outflow -1.54 8.11 -40.10 19.01 -116.44 134.87 8.77 -279.87 279.56 -0.93 Opening Cash & Equivalents 21.67 13.56 53.66 35.58 144.25 9.45 0.68 280.56 0.99 5.34 Closing Cash & Equivalent 20.13 21.67 13.56 53.66 28.22 144.25 9.45 0.69 280.55 4.41

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 803.21 723.94 552.35 1,463.38 449.15 811.97 312.42 328.55 947.65 171.76 PBT 631.83 354.59 625.39 1,368.08 999.82 749.32 541.27 529.09 936.31 359.07 Adjustment 286.86 487.61 417.75 102.42 278.28 117.57 87.12 83.06 69.45 44.61 Changes in Working Capital -95.63 -57.56 -367.36 238.30 -592.84 111.56 -180.85 -165.64 138.90 -162.50 Cash after chg. in Working capital 823.06 784.64 675.78 1,708.80 685.26 978.45 447.54 446.51 1,144.66 241.18 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -19.85 -60.70 -123.43 -245.42 -236.11 -166.48 -135.12 -117.96 -197.01 -69.42 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -320.61 -447.59 -371.97 -838.80 -731.63 -755.60 -884.38 -485.91 -306.80 -255.61 Net Fixed Assets -340.94 994.77 -402.51 -1,303.18 -789.71 -638.70 -606.86 -121.60 -288.80 -200.26 Net Investments 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 0.00 Others 17.74 -1,432.45 -93.19 -25.78 384.94 90.60 -81.67 -298.73 -13.87 -55.35 Cash from Financing Activity -437.87 -261.96 -217.35 -597.42 154.85 59.03 502.63 -128.88 -224.30 86.72 Net Cash Inflow / Outflow 44.73 14.39 -36.97 27.16 -127.63 115.40 -69.33 -286.24 416.55 2.86 Opening Cash & Equivalents 75.48 61.09 98.06 71.83 199.06 83.74 153.07 439.32 22.77 23.96 Closing Cash & Equivalent 120.21 75.48 61.09 98.06 71.84 199.07 83.74 153.08 439.32 26.83

Financial Ratios

Consolidated /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 249.75 224.59 269.16 259.57 177.51 143.89 116.43 99.06 81.21 44.22 ROA 10.74% 5.24% 7.73% 17.18% 18.32% 14.39% 13.15% 17.21% 35.93% 20.27% ROE 14.30% 7.15% 10.46% 25.96% 32.00% 24.91% 20.78% 25.35% 59.11% 39.17% ROCE 14.62% 7.20% 11.72% 25.40% 27.08% 23.66% 22.91% 32.46% 71.75% 41.44% Fixed Asset Turnover 1.61 1.67 1.94 2.41 2.59 2.82 2.79 2.94 3.19 2.77 Receivable days 78.96 77.61 51.11 43.44 58.46 57.91 67.48 51.27 43.03 53.70 Inventory Days 81.66 94.70 99.26 86.99 86.76 77.85 77.12 67.74 55.57 62.20 Payable days 123.25 128.19 133.30 128.78 54.44 74.24 86.97 79.07 76.51 69.76 Cash Conversion Cycle 37.36 44.12 17.08 1.65 90.78 61.52 57.63 39.94 22.09 46.14 Total Debt/Equity 0.09 0.14 0.12 0.10 0.50 0.39 0.28 0.00 0.00 0.23 Interest Cover 13.93 8.06 39.66 104.06 47.32 52.42 242.09 172.25 249.37 116.70

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 245.14 222.36 266.47 257.80 170.79 144.24 117.78 100.92 84.74 46.93 ROA 9.93% 5.15% 7.34% 17.22% 14.64% 13.15% 12.25% 14.97% 33.76% 18.76% ROE 13.40% 7.12% 10.11% 26.91% 26.97% 24.00% 20.42% 23.25% 58.03% 36.24% ROCE 13.42% 7.44% 11.25% 26.28% 23.30% 22.66% 22.15% 28.87% 65.87% 37.54% Fixed Asset Turnover 1.70 1.79 1.97 2.31 2.52 2.85 2.86 3.07 3.24 2.71 Receivable days 60.69 59.84 39.75 41.06 53.64 47.09 50.43 40.13 41.02 55.91 Inventory Days 91.38 99.60 106.49 90.48 85.38 78.91 79.67 70.01 54.91 61.11 Payable days 150.62 148.04 173.51 187.92 69.87 88.23 98.47 84.03 80.04 69.83 Cash Conversion Cycle 1.45 11.40 -27.27 -56.39 69.15 37.76 31.63 26.12 15.89 47.19 Total Debt/Equity 0.09 0.15 0.12 0.10 0.54 0.42 0.32 0.05 0.07 0.30 Interest Cover 12.24 8.07 36.27 86.40 37.81 41.70 160.20 102.16 173.43 95.30

Top Investors:

dsp midcap fund

life insurance corporation of india

kotak small cap fund

tata aia life insurance co ltd unit linked multi cap fund

investor education and protection fund (iepf)

llp

Annual Reports:

News Update:

Alembic Pharmaceuticals receives USFDA’s final approval for Ticagrelor Tablets
2nd May 2025, 17:34 PM

The company has a cumulative total of 222 ANDA approvals from USFDA
Read More
Alembic Pharmaceuticals commissions new manufacturing facility in Madhya Pradesh
26th Apr 2025, 15:20 PM

The investment made for said manufacturing facility is approximately Rs 205 crore
Read More
Alembic Pharmaceuticals gets USFDA’s nod for Carbamazepine Tablets
17th Apr 2025, 14:20 PM

Alembic has a cumulative total of 222 ANDA approvals (196 final approvals and 26 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals receives USFDA’s final approval for Pantoprazole Sodium Injection
1st Apr 2025, 16:30 PM

Alembic has a cumulative total of 221 ANDA approvals from USFDA
Read More
Alembic Pharmaceuticals completes USFDA inspection for API-III Facility at Karakhadi
22nd Mar 2025, 10:18 AM

The inspection was conducted from March 17, 2025 to March 21, 2025
Read More
Alembic Pharmaceuticals’ arm incorporates wholly-owned subsidiary in USA
18th Mar 2025, 11:30 AM

Alembic Global Holding SA will be making a remittance to Alembic LifeSciences Inc. towards subscription of 100% shareholding
Read More
USFDA concludes inspection at Alembic Pharmaceuticals’ Vadodara facility
10th Mar 2025, 10:07 AM

The USFDA issued a form 483 with one procedural observation
Read More
Alembic Pharma - Quarterly Results
3rd Feb 2025, 14:37 PM

Read More

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: